title: Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
abstract: Although temozolomide (TMZ) replaced nitrosoureas as the standard initial chemotherapy for glioblastoma (GBM), no studies have compared TMZ with nimustine (ACNU), a nitrosourea agent widely used in central Europe and most Asian regions. One hundred thirty-five patients with GBM who underwent extensive tumor resection in our institution received both radiation and chemotherapy as initial treatment, 34 received TMZ and 101 ACNU-based (ACNU plus teniposide or cisplatin) chemotherapy. Efficacy analysis included overall survival (OS) and progression-free survival (PFS). The following prognostic factors were taken into account: age, performance status, extent of resection, and O(6)-methylguanine-DNA-methyltransferase (MGMT) gene status. The median OS was superior in the TMZ versus the ACNU group (p = 0.011), although MGMT gene silencing, which is associated with a striking survival benefit from alkylating agents, was more frequent in the ACNU group. In multivariate Cox analysis adjusting for the common prognostic factors, TMZ chemotherapy independently predicted a favorable outcome (p = 0.002 for OS, hazard ratio [HR], 0.45; p = 0.011 for PFS, HR, 0.56). Given that >40 % of patients in ACNU group did not receive the intensive chemotherapy cycles because of severe hematological and nonhematological toxicity, we performed a further subanalysis for patients who received at least 4 cycles of chemotherapy. Although a modest improvement in survival occurred in this ACNU subgroup, the efficacy was still inferior to that in the TMZ cohort. Our data suggest that the survival benefit of TMZ therapy is superior to that of an ACNU-based regimen in patients with extensive tumor resection, also shows greater tolerability.
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.6 Tiantan Xili, Dongcheng District, Beijing, 100050, China.
authors.forename: Yongzhi
authors.initials: Y
authors.lastname: Wang
authors.forename: Xuzhu
authors.initials: X
authors.lastname: Chen
authors.forename: Zhong
authors.initials: Z
authors.lastname: Zhang
authors.forename: Shouwei
authors.initials: S
authors.lastname: Li
authors.forename: Baoshi
authors.initials: B
authors.lastname: Chen
authors.forename: Chenxing
authors.initials: C
authors.lastname: Wu
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Xinzhong
authors.initials: X
authors.lastname: Zhang
authors.forename: Jiayin
authors.initials: J
authors.lastname: Wang
authors.forename: Ling
authors.initials: L
authors.lastname: Chen
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D059186:Chemoradiotherapy, Adjuvant; D003131:Combined Modality Therapy; D015254:DNA Modification Methylases / Q000235:genetics; D045643:DNA Repair Enzymes / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D006801:Humans; D053208:Kaplan-Meier Estimate; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D015376:Nimustine / Q000009:adverse effects / Q000627:therapeutic use*; D016019:Survival Analysis; D000077204:Temozolomide; D025521:Tumor Suppressor Proteins / Q000235:genetics; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D025521:Tumor Suppressor Proteins; D015376:Nimustine; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide
references.citation: Lancet Oncol. 2006 May;7(5):392-401
references.pmid: 16648043
references.citation: PLoS One. 2012;7(4):e34588
references.pmid: 22511951
references.citation: J Neurooncol. 2008 May;88(1):57-63
references.pmid: 18253699
references.citation: Cancer Chemother Pharmacol. 1998;42(6):433-40
references.pmid: 9788568
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3276-84
references.pmid: 12947063
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1375-82
references.pmid: 11870182
references.citation: Lancet. 2002 Mar 23;359(9311):1011-8
references.pmid: 11937180
references.citation: J Clin Oncol. 2007 Sep 10;25(26):4127-36
references.pmid: 17827463
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Cancer. 2012 Nov 15;118(22):5595-600
references.pmid: 22517216
references.citation: Cancer. 1993 Apr 15;71(8):2585-97
references.pmid: 8453582
references.citation: Cancer J. 2012 Jan-Feb;18(1):20-5
references.pmid: 22290253
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: J Neurooncol. 2009 Jan;91(2):221-5
references.pmid: 18813874
references.citation: J Clin Oncol. 1990 Jul;8(7):1277-80
references.pmid: 2358840
references.citation: J Neurosurg. 2009 Jan;110(1):156-62
references.pmid: 18847342
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5743-50
references.pmid: 19805672
references.citation: Int J Clin Oncol. 2010 Aug;15(4):352-8
references.pmid: 20232102